不妊治療薬の市場規模、シェア、動向分析レポート：薬物クラス別（ゴナドトロピン、アロマターゼ阻害剤、SERM、ドパミンアゴニスト）、最終用途別（男性、女性）、流通チャネル別、地域別、セグメント予測、2023年～2030年

不妊治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、不妊治療薬の世界市場規模は2023年から2030年にかけてCAGR6.1%で拡大し、2030年には56億米ドルに達すると予測されています。市場は飽和状態にあり、新規参入のチャンスは少ないと思われます。この市場には、Merck &Co.Inc.、Ferring B.V.、Organonグループ企業などが市場シェアの大半を占めています。そのため、製薬会社はゴナドトロピンのバイオシミラー医薬品の開発に注力し、市場開拓を進めています。例えば、Qilu Pharmaceutical Co., Ltd.は、組み換えヒト卵胞刺激ホルモンであるQL1012の開発に注力しており、現在、第3相臨床試験を実施中です。臨床試験が成功裏に終了し、その後発売されれば、市場を牽引することが期待されます。

不妊症患者を支援するための公的機関や民間機関による取り組みが増加していることは、不妊症治療市場の成長にプラスに働くと予想されます。例えば、フランス政府は2022年3月に体外受精法を導入し、独身女性や同性カップルは同国の国民医療制度のもとで無料で治療を受けられるようになりました。

また、2022年11月には、サウジアラビアの医療保険審議会が、医薬品を医療保険の適用範囲に含めることに関する調査を実施しました。この研究が成功し、医薬品が保険適用となることで、患者の治療へのアクセスが向上し、その後、予測期間中に医薬品の需要が増加すると予測されます。

患者や医師の間で疾患や利用可能な医薬品に関する認識が高まっていることから、市場の対象人口が増加すると予測されます。例えば、2021年9月にムバダラ・ヘルス社とユナイテッド・イースタン・メディカル・サービス社（UEMedical）は、ドバイでこの疾患の治療の進歩やその利点について医師や患者の認識を高める目的で、「第3回ヘルスプラス中東不妊会議」を開催しています。

また、少子化対策や出産促進を目的とした政府の取り組みもあり、薬剤の需要が高まる可能性があります。例えば、2022年8月、韓国政府は、同国の少子化問題に取り組み、出産を奨励する目的で、家族に新たに生まれた子ども1人につき毎月740米ドルを支給する規定を発表しています。

不妊治療薬市場レポートハイライト

薬物クラス別では、2022年にゴナドトロピンセグメントが市場で最大のシェアを占め、予測期間中に最も速い成長を遂げると予想されます。これは、不妊症に対するFDA承認のゴナドトロピンが市場で入手可能であることに起因しています。

最終用途別では、PCOS、HPV関連膣がん、子宮筋腫など、女性における疾患の発生率が上昇していることから、2022年には女性セグメントが不妊治療薬市場を独占することになります。2022年4月には、20～49歳のフランス人女性の約1.5％が不妊症と診断されるとのコホート研究が発表されています。

2022年の不妊治療薬市場は、ホスピタルファーマシーセグメントが支配的でした。この成長は、世界的にこの症状の診断と治療のための入院患者の増加によるものと考えられます

医療従事者の不妊症に対する意識の高さ、薬剤の入手のしやすさ、疾患の有病率の上昇などの要因により、2022年の世界市場は北米が優位に立ちました。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • セグメントの範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース：
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査内容
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ：商品フローアプローチ
• 調査の仮定
• 二次情報一覧
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場のスナップショット
• セグメントのスナップショット
• 競合のスナップショット

第3章 不妊治療薬：市場変数、動向、および範囲

• 市場系列の見通し
  • 女性の健康市場
• 浸透と成長の見通しのマッピング
• 規制状況
• 市場力学
• 市場促進要因分析
  • 不妊の負担増
  • 強力な製品パイプラインの存在
  • 不妊症の研究開発への資金提供を増やす
• 市場抑制要因分析
  • 不妊治療薬に対する非協力的な政府規制
• PESTEL分析
• 業界分析- ポーターの5つの力
• パイプライン分析

第4章 不妊治療薬市場：セグメント分析、薬剤クラス別、2018年から2030年（100万米ドル）

• 不妊治療薬市場：薬物クラスの変動分析
• ゴナドトロピン
  • アロマターゼ阻害剤
  • 選択的エストロゲン受容体モジュレーター（SERM）
  • ドーパミン作動薬
  • その他

第5章 不妊治療薬市場：セグメント分析、流通チャネル別、2018年から2030年（100万米ドル）

• 不妊治療薬市場：流通チャネル変動分析
• 病院薬局
• 専門および小売薬局
• オンライン薬局

第6章 不妊治療薬市場：セグメント分析、最終用途別、2018年から2030年（100万米ドル）

• 不妊治療薬市場：エンドユーザーの変動分析
• 男性
• 女性

第7章 不妊治療薬市場：地域の推定・動向分析

• 北米
  • SWOT分析：
  • 米国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • カナダ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 欧州
  • SWOT分析：
  • 英国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
    • 処方箋と調剤のシナリオ
  • ドイツ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • フランス
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • イタリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スペイン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • デンマーク
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • スウェーデン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • ノルウェー
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• アジア太平洋地域
  • SWOT分析：
  • 日本
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
    • 処方箋と調剤のシナリオ
  • 中国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • インド
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • オーストラリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • 韓国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • タイ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• ラテンアメリカ
  • SWOT分析：
  • ブラジル
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
    • 処方箋と調剤のシナリオ
  • メキシコ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アルゼンチン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
• 中東およびアフリカ（MEA）
  • SWOT分析：
  • 南アフリカ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
    • 処方箋と調剤のシナリオ
  • サウジアラビア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ
  • クウェート
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
    • 償還シナリオ

第8章 不妊治療薬市場：競合分析

• 主要な市場参入企業別最近の動向と影響分析
  • 新製品の発売
  • 合併と買収
  • ライセンシング契約
  • カンファレンスとキャンペーン
• 会社の分類
  • イノベーター
  • 市場のリーダー
• ベンダー情勢
  • 主要なディストリビューターとチャネルパートナーのリスト
  • 主要顧客
• 公開会社
  • 主要企業の市場シェア分析、2021年
  • 会社の市況分析
  • ヒートマップ分析
  • 競合ダッシュボード分析
    • 市場の差別化要因
• 非公開会社
  • 主要新興企業一覧
  • 地域ネットワークマップ
• 企業プロファイル
  • Bayer AG
  • Company Overview
  • Financial Performance
  • Product Benchmarking
  • Strategic Initiatives
• ノバルティスAG
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• メルク社
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• フェリング BV
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• ファイザー社
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• 人類製薬
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• テバ製薬工業株式会社。
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• サノフィ
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• アボット
  • 会社概要
  • 財務実績
  • 製品のベンチマーク
  • 戦略的イニシアチブ
• オルガノン・グループ・オブ・カントリー
  • 会社概要
  • 製品のベンチマーク
  • 戦略的イニシアチブ

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Regulatory Framework
• Table 4 Global Infertility Drugs Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 6 Global Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 7 Global Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 8 North America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 10 North America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 11 North America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 13 U.S. Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 14 U.S. Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 15 Canada Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 16 Canada Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 17 Canada Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 18 Europe Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 19 Europe Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 20 Europe Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 21 Europe Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Germany Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 23 Germany Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 24 Germany Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 UK Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 26 UK Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 27 UK Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 France Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 29 France Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 30 France Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 31 Italy Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 32 Italy Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 33 Italy Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 34 Spain Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 35 Spain Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 36 Spain Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Denmark Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 38 Denmark Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 39 Denmark Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 40 Sweden Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 41 Sweden Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 42 Sweden Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Norway Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 44 Norway Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 45 Norway Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 50 Japan Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 51 Japan Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 52 Japan Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 China Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 54 China Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 55 China Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 56 India Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 57 India Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 58 India Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 59 South Korea Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 60 South Korea Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 61 South Korea Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 Australia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 63 Australia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 64 Australia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 65 Thailand Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 66 Thailand Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 67 Thailand Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Latin America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Latin America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 70 Latin America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 71 Latin America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 72 Brazil Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 73 Brazil Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 74 Brazil Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 75 Mexico Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 76 Mexico Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 77 Mexico Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 78 Argentina Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 79 Argentina Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 80 Argentina Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 84 Middle East & Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 88 South Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 89 South Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 90 South Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 91 UAE Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 92 UAE Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 93 UAE Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Kuwait Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 95 Kuwait Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
• Table 96 Kuwait Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Infertility Drugs Market Segmentation
• Fig. 2 Market Research Process
• Fig. 3 Data Triangulation Techniques
• Fig. 4 Primary Research Pattern
• Fig. 5 Market Research Approaches
• Fig. 6 Value-Chain-Based Sizing & Forecasting
• Fig. 7 QFD Modeling for Market Share Assessment
• Fig. 8 Market Formulation & Validation
• Fig. 9 Commodity Flow Analysis
• Fig. 10 Market Snapshot (2022) (USD Million)
• Fig. 11 Segment Snapshot (2022) (USD Million)
• Fig. 12 Segment Snapshot (2022) (USD Million)
• Fig. 13 Competitive Snapshot
• Fig. 14 Penetration and Growth Prospect Mapping
• Fig. 15 Infertility Drugs Market Driver Impact
• Fig. 16 Infertility Drugs Market Restraint Impact
• Fig. 17 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
• Fig. 18 Porter's Five Forces Analysis
• Fig. 19 Infertility Drugs Market: Drug Class Outlook and Key Takeaways
• Fig. 20 Infertility Drugs Market: Drug Class Movement Analysis
• Fig. 21 Gonadotropins Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 22 Aromatase Inhibitors Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 23 Selective Estrogen Receptor Modulators (SERMs) Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 24 Dopamine Agonists Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 25 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 26 Infertility Drugs Market: Distribution Channe Outlook and Key Takeaways
• Fig. 27 Infertility Drugs Market: Distribution Channel Movement Analysis
• Fig. 28 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 29 Specialty & Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 30 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 31 Infertility Drugs Market: End-User Outlook and Key Takeaways
• Fig. 32 Infertility Drugs Market: End-User Movement Analysis
• Fig. 33 Men Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 34 Women Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 35 Regional Marketplace: Key Takeaways
• Fig. 36 North America: SWOT analysis
• Fig. 37 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 38 U.S. Key Country Dynamics
• Fig. 39 U.S. Target Disease Prevalence
• Fig. 40 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Canada Key Country Dynamics
• Fig. 42 Canada Target Disease Prevalence
• Fig. 43 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Europe: SWOT analysis
• Fig. 45 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Germany Key Country Dynamics
• Fig. 47 Germany Target Disease Prevalence
• Fig. 48 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UK Key Country Dynamics
• Fig. 50 UK Target Disease Prevalence
• Fig. 51 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 52 France Key Country Dynamics
• Fig. 53 France Target Disease Prevalence
• Fig. 54 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Italy Key Country Dynamics
• Fig. 56 Italy Target Disease Prevalence
• Fig. 57 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Spain Key Country Dynamics
• Fig. 59 Spain Target Disease Prevalence
• Fig. 60 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Denmark Key Country Dynamics
• Fig. 62 Denmark Target Disease Prevalence
• Fig. 63 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Sweden Key Country Dynamics
• Fig. 65 Sweden Target Disease Prevalence
• Fig. 66 Sweden Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Norway Key Country Dynamics
• Fig. 68 Norway Target Disease Prevalence
• Fig. 69 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Rest of Europe Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Asia Pacific: SWOT Analysis
• Fig. 72 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Japan Key Country Dynamics
• Fig. 74 Japan Target Disease Prevalence
• Fig. 75 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 China Key Country Dynamics
• Fig. 77 China Target Disease Prevalence
• Fig. 78 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 79 India Key Country Dynamics
• Fig. 80 India Target Disease Prevalence
• Fig. 81 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Australia Key Country Dynamics
• Fig. 83 Australia Target Disease Prevalence
• Fig. 84 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 85 South Korea Key Country Dynamics
• Fig. 86 South Korea Target Disease Prevalence
• Fig. 87 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Thailand Key Country Dynamics
• Fig. 89 Thailand Target Disease Prevalence
• Fig. 90 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Rest of APAC Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Latin America (LATAM): SWOT Analysis
• Fig. 93 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Brazil Key Country Dynamics
• Fig. 95 Brazil Target Disease Prevalence
• Fig. 96 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Mexico Key Country Dynamics
• Fig. 98 Mexico Target Disease Prevalence
• Fig. 99 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Argentina Key Country Dynamics
• Fig. 101 Argentina Target Disease Prevalence
• Fig. 102 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Rest of LATAM Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Middle East & Africa (MEA): SWOT Analysis
• Fig. 105 Middle East & Africa (MEA) Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 106 South Africa Key Country Dynamics
• Fig. 107 Target Disease Prevalence
• Fig. 108 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Saudi Arabia Key country dynamics
• Fig. 110 Saudi Arabia Target Disease Prevalence
• Fig. 111 Saudi Arabia Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 UAE Key Country Dynamics
• Fig. 113 UAE Target Disease Prevalence
• Fig. 114 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 115 Kuwait Key Country Dynamics
• Fig. 116 Kuwait Target Disease Prevalence
• Fig. 117 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 118 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 119 Heat Map Analysis
• Fig. 120 Strategic Framework

Infertility Drugs Market Growth & Trends:

The global infertility drugs market size is expected to reach USD 5.6 billion by 2030 expanding at a CAGR of 6.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. The market seems to be saturated with fewer opportunities for new entrants. The companies including Merck & Co. Inc., Ferring B.V., and Organon group of companies holds majority of market share. Thus, the pharmaceutical companies are focusing on developing biosimilar of gonadotropins for market penetration. For instance, Qilu Pharmaceutical Co., Ltd. focuses on developing QL1012, a recombinant human follicle stimulating hormone which is under phase 3 clinical trial. Successful completion of of trial and subsequent launch is anticipated to drive market.

Increasing initiatives undertaken by public and private organizations to support patients living with infertility are expected to positively contribute to infertility treatment market growth. For instance, in March 2022, the French government introduced new IVF law under which single women and same sex-couple avail treatment free of cost under the country's national healthcare system.

In addition, in November 2022, Saudi Arabia's Health Insurance Council conducted studies with regard to the inclusion of medicines under medical insurance coverage. The successful completion of the study and inclusion of medication under insurance is anticipated to increase patient access to treatment, subsequently, increase demand for medicines over the forecast period.

Rising awareness about disease and its available medicines among patients and physicians is anticipated to increase the target population for the market. For instance, in September 2021, Mubadala Health and United Eastern Medical Services (UEMedical) organized the '3rd HealthPlus Middle East Fertility Conference with an aim to rise awareness about the advancements in the treatment of this conditions and its benefits among physicians and patients in Dubai.

Moreover, there are several initiatives undertaken by the national government worldwide to tackle low fertility rate issues and promote childbirth which may increase the demand for drugs. For instance, in August 2022, the South Korean Government announced a provision for a monthly allowance of USD 740 per new child born in the family with an aim to tackle the low fertility rate in the country and encourage childbirth.

Infertility Drugs Market Report Highlights:

• By drug class, the gonadotropin segment accounted for the largest share of the market in 2022 and is anticipated to witness fastest growth over the forecast period. This can be attributed to the availability of FDA-approved gonadotropins for infertility conditions in the market

• Based on end-user, the women segment dominated the infertility drugs market in 2022 owing to the rising incidence of the diseases such as PCOS, HPV associated vaginal cancer, uterine fibroids in women. As per the cohort studies published, in April 2022, approximately 1.5% of all French women aged 20 to 49 years were diagnosed with this condition annually.

• Hospiatal pharmacy segment dominated the infertility drugs market in 2022. This growth can be attributed to an increase in inpatient visits for the diagnosis and consulation of this condition worldwide

• North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about infertility conditions, ease of availability of drugs, and an increase in disease prevalence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation and Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Snapshot

Chapter 3 Infertility Drugs: Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Women's Health Market
• 3.2 Penetration and Growth Prospect Mapping
• 3.3 Regulatory Landscape
• 3.4 Market Dynamics
• 3.5 Market Driver Analysis
  • 3.5.1 Rising burden of infertility
  • 3.5.2 Presence of strong product pipeline
  • 3.5.3 Increasing funding for infertility R&D
• 3.6 Market Restraint Analysis
  • 3.6.1. Unsupportive Government Regulations for Infertility Drugs
• 3.7 PESTEL Analysis
• 3.8 Industry Analysis-Porter's Five Forces
• 3.9 Pipeline Analysis

Chapter 4 Infertility Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

• 4.1 Infertility Drugs Market: Drug Class Movement Analysis
• 4.2 Gonadotropins
  • 4.2.1 Gonadotropins Market, 2018 - 2030 (USD Million)
  • 4.2.2 Aromatase Inhibitors
    • 4.2.2.1 Aromatase Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.2.3 Selective Estrogen Receptor Modulators (SERMs)
    • 4.2.3.1 Selective Estrogen Receptor Modulators (SERMs) Market, 2018 - 2030 (USD Million)
  • 4.2.4 Dopamine Agonists
    • 4.2.4.1 Dopamine Agonists Market, 2018 - 2030 (USD Million)
  • 4.2.5 Others
    • 4.2.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Infertility Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 5.1 Infertility Drugs Market: Distribution Channel Movement Analysis
• 5.2 Hospital Pharmacy
  • 5.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 5.3 Specialty & Retail Pharmacy
  • 5.3.1 Specialty & Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 5.4 Online Pharmacy
  • 5.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6 Infertility Drugs Market: Segment Analysis, by End-User, 2018 - 2030 (USD Million)

• 6.1 Infertility Drugs Market: End-User Movement Analysis
• 6.2 Men
  • 6.2.1 Men Market, 2018 - 2030 (USD Million)
• 6.3 Women
  • 6.3.1 Women Market, 2018 - 2030 (USD Million)

Chapter 7 Infertility Drugs Market: Regional Estimates and Trend Analysis

• 7.1 North America
  • 7.1.1 SWOT Analysis:
    • 7.1.1.1 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.1.2 U.S.
    • 7.1.2.1 Key Country Dynamics
    • 7.1.2.2 Target Disease Prevalence
    • 7.1.2.3 Competitive Scenario
    • 7.1.2.4 Regulatory Framework
    • 7.1.2.5 Reimbursement Scenario
    • 7.1.2.6 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.1.3 Canada
    • 7.1.3.1 Key Country Dynamics
    • 7.1.3.2 Target Disease Prevalence
    • 7.1.3.3 Competitive Scenario
    • 7.1.3.4 Regulatory Framework
    • 7.1.3.5 Reimbursement Scenario
    • 7.1.3.6 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.2 Europe
  • 7.2.1 SWOT Analysis:
    • 7.2.1.1 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 UK
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 Target Disease Prevalence
    • 7.2.2.3 Competitive Scenario
    • 7.2.2.4 Regulatory Framework
    • 7.2.2.5 Reimbursement Scenario
    • 7.2.2.6 Prescription and Dispensing Scenario
    • 7.2.2.7 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3 Germany
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Target Disease Prevalence
    • 7.2.3.3 Competitive Scenario
    • 7.2.3.4 Regulatory Framework
    • 7.2.3.5 Reimbursement Scenario
    • 7.2.3.6 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4 France
    • 7.2.4.1 Key Country Dynamics
    • 7.2.4.2 Target Disease Prevalence
    • 7.2.4.3 Competitive Scenario
    • 7.2.4.4 Regulatory Framework
    • 7.2.4.5 Reimbursement Scenario
    • 7.2.4.6 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.5 Italy
    • 7.2.5.1 Key Country Dynamics
    • 7.2.5.2 Target Disease Prevalence
    • 7.2.5.3 Competitive Scenario
    • 7.2.5.4 Regulatory Framework
    • 7.2.5.5 Reimbursement Scenario
    • 7.2.5.6 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.6 Spain
    • 7.2.6.1 Key Country Dynamics
    • 7.2.6.2 Target Disease Prevalence
    • 7.2.6.3 Competitive Scenario
    • 7.2.6.4 Regulatory Framework
    • 7.2.6.5 Reimbursement Scenario
    • 7.2.6.6 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.7 Denmark
    • 7.2.7.1 Key Country Dynamics
    • 7.2.7.2 Target Disease Prevalence
    • 7.2.7.3 Competitive Scenario
    • 7.2.7.4 Regulatory Framework
    • 7.2.7.5 Reimbursement Scenario
    • 7.2.7.6 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.8 Sweden
    • 7.2.8.1 Key Country Dynamics
    • 7.2.8.2 Target Disease Prevalence
    • 7.2.8.3 Competitive Scenario
    • 7.2.8.4 Regulatory Framework
    • 7.2.8.5 Reimbursement Scenario
    • 7.2.8.6 Sweden Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.9 Norway
    • 7.2.9.1 Key Country Dynamics
    • 7.2.9.2 Target Disease Prevalence
    • 7.2.9.3 Competitive Scenario
    • 7.2.9.4 Regulatory Framework
    • 7.2.9.5 Reimbursement Scenario
    • 7.2.9.6 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.9 Rest of Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Asia Pacific
  • 7.3.1 SWOT Analysis:
    • 7.3.1.1 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 Japan
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 Target Disease Prevalence
    • 7.3.2.3 Competitive Scenario
    • 7.3.2.4 Regulatory Framework
    • 7.3.2.5 Reimbursement Scenario
    • 7.3.2.6 Prescription and Dispensing Scenario
    • 7.3.2.7 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3 China
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Target Disease Prevalence
    • 7.3.3.3 Competitive Scenario
    • 7.3.3.4 Regulatory Framework
    • 7.3.3.5 Reimbursement Scenario
    • 7.3.3.6 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4 India
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 Target Disease Prevalence
    • 7.3.4.3 Competitive Scenario
    • 7.3.4.4 Regulatory Framework
    • 7.3.4.5 Reimbursement Scenario
    • 7.3.4.6 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5 Australia
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Target Disease Prevalence
    • 7.3.5.3 Competitive Scenario
    • 7.3.5.4 Regulatory Framework
    • 7.3.5.5 Reimbursement Scenario
    • 7.3.5.6 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6 South Korea
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Target Disease Prevalence
    • 7.3.6.3 Competitive Scenario
    • 7.3.6.4 Regulatory Framework
    • 7.3.6.5 Reimbursement Scenario
    • 7.3.6.6 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7 Thailand
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Target Disease Prevalence
    • 7.3.7.3 Competitive Scenario
    • 7.3.7.4 Regulatory Framework
    • 7.3.7.5 Reimbursement Scenario
    • 7.3.7.6 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8 Rest of APAC Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Latin America
  • 7.4.1 SWOT Analysis:
    • 7.4.1.1 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Brazil
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Target Disease Prevalence
    • 7.4.2.3 Competitive Scenario
    • 7.4.2.4 Regulatory Framework
    • 7.4.2.5 Reimbursement Scenario
    • 7.4.2.6 Prescription and Dispensing Scenario
    • 7.4.2.7 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3 Mexico
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 Target Disease Prevalence
    • 7.4.3.3 Competitive Scenario
    • 7.4.3.4 Regulatory Framework
    • 7.4.3.5 Reimbursement Scenario
    • 7.4.3.6 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4 Argentina
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 Target Disease Prevalence
    • 7.4.4.3 Competitive Scenario
    • 7.4.4.4 Regulatory Framework
    • 7.4.4.5 Reimbursement Scenario
    • 7.4.4.6 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. Rest of Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Middle East & Africa (MEA)
  • 7.5.1 SWOT Analysis:
    • 7.5.1.1 MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 South Africa
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Target Disease Prevalence
    • 7.5.2.3 Competitive Scenario
    • 7.5.2.4 Regulatory Framework
    • 7.5.2.5 Reimbursement Scenario
    • 7.5.2.6 Prescription and Dispensing Scenario
    • 7.5.2.7 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3 Saudi Arabia
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Target Disease Prevalence
    • 7.5.3.3 Competitive Scenario
    • 7.5.3.4 Regulatory Framework
    • 7.5.3.5 Reimbursement Scenario
    • 7.5.3.6 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4 UAE
    • 7.5.4.1 Key Country Dynamics
    • 7.5.4.2 Target Disease Prevalence
    • 7.5.4.3 Competitive Scenario
    • 7.5.4.4 Regulatory Framework
    • 7.5.4.5 Reimbursement Scenario
    • 7.5.4.6 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5 Kuwait
    • 7.5.5.1 Key Country Dynamics
    • 7.5.5.2 Target Disease Prevalence
    • 7.5.5.3 Competitive Scenario
    • 7.5.5.4 Regulatory Framework
    • 7.5.5.5 Reimbursement Scenario
    • 7.5.5.6 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Infertility Drugs Market: Competitive Analysis

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 New Product Launch
  • 8.1.2 Merger and Acquisition
  • 8.1.3 Licensing Agreements
  • 8.1.4 Conferences and Campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market Leaders
• 8.3 Vendor Landscape
  • 8.3.1 List of Key Distributors and Channel Partners
  • 8.3.2 Key Customers
• 8.4 Public Companies
  • 8.4.1 Key Company Market Share Analysis, 2021
  • 8.4.2 Company Market Position Analysis
  • 8.4.3 Heat Map Analysis
  • 8.4.4 Competitive Dashboard Analysis
    • 8.4.4.1 Market Differentiators
• 8.5 Private Companies
  • 8.5.1 List of Key Emerging Companies
  • 8.5.2 Regional Network Map
• 8.6 Company Profiles
  • 8.6.1.Bayer AG
  • 8.6.1.1 Company Overview
  • 8.6.1.2 Financial Performance
  • 8.6.1.3 Product Benchmarking
  • 8.6.1.4 Strategic Initiatives
  • 8.6.2 Novartis AG
    • 8.6.2.1 Company Overview
    • 8.6.2.2 Financial Performance
    • 8.6.2.3 Product Benchmarking
    • 8.6.2.4 Strategic Initiatives
  • 8.6.3 Merck & Co., Inc.
    • 8.6.3.1 Company Overview
    • 8.6.3.2 Financial Performance
    • 8.6.3.3 Product Benchmarking
    • 8.6.3.4 Strategic Initiatives
  • 8.6.4 Ferring B.V.
    • 8.6.4.1 Company Overview
    • 8.6.4.2 Financial Performance
    • 8.6.4.3 Product Benchmarking
    • 8.6.4.4 Strategic Initiatives
  • 8.6.5 Pfizer Inc.
    • 8.6.5.1 Company Overview
    • 8.6.5.2 Financial Performance
    • 8.6.5.3 Product Benchmarking
    • 8.6.5.4 Strategic Initiatives
  • 8.6.6 Mankind Pharma
    • 8.6.6.1 Company Overview
    • 8.6.6.2 Financial Performance
    • 8.6.6.3 Product Benchmarking
    • 8.6.6.4 Strategic Initiatives
  • 8.6.7 Teva Pharmaceutical Industries LTD.
    • 8.6.7.1 Company Overview
    • 8.6.7.2 Financial Performance
    • 8.6.7.3 Product Benchmarking
    • 8.6.7.4 Strategic Initiatives
  • 8.6.8 Sanofi
    • 8.6.8.1 Company Overview
    • 8.6.8.2 Financial Performance
    • 8.6.8.3 Product Benchmarking
    • 8.6.8.4 Strategic Initiatives
  • 8.6.9 Abbott
    • 8.6.8.1 Company Overview
    • 8.6.9.2 Financial Performance
    • 8.6.9.3 Product Benchmarking
    • 8.6.9.4 Strategic Initiatives
  • 8.6.10 Organon Group of Countries
    • 8.6.10.1 Company Overview
    • 8.6.10.2 Product Benchmarking
    • 8.6.10.3 Strategic Initiatives